MIstiQU-MED AtoMIc-based Quantum magnetometry meets Ultrasound for Medical Early Detection
- Coordinator
- Sorbonne Universite, France
- Runs
- 1 November 2026 to 30 April 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335039
What the project is doing
In the project's own words, from its summary on CORDIS.
MIstiQU-MED addresses a central gap in medical diagnostics: most imaging modalities detects disease once it becomes morphologically visible, while earlier functional changes in tissue remain inaccessible. Early malignancy and internal injury alter ion transport and membrane polarization, producing shifts in electrical conductivity (σ) and permittivity (ε), but today these contrasts are difficult to measure in vivo at depth with portable systems because electrical methods rely on electrode coupling, and weak inductive signals.
MIstiQU-MED proposes a proof-of-concept project to establish the feasibility of MHz-band quantum readout of conductivity and permittivity contrasts generated by ultrasound excitation, in an unshielded environment, with controlled phantom samples. The project will develop a magneto-acoustic sensing architecture in which a phased ultrasound array localizes a RF Lorentz current inside tissue, and a warm-vapor atomic magnetometer reads the resulting RF magnetic field with phase-sensitive demodulation to separate σ and ε channels.
Objectives are to (i) engineer the acoustic–magnetometer coupling geometry and bias-field module, (ii) implement coherent optical readout and narrowband rejection of external RF backgrounds using the PI’s ERC CoG atomic-coherence toolkit, and (iii) validate sensitivity, spatial selectivity, and reconstruction in heterogeneous tissue phantoms representative of breast cancer and/or trauma. The high-risk research part is achieving pT-level detection without magnetic shielding by operating in the ultrasound MHz band and synchronously extracting the signal; the high-gain outcome is a validated phantom-level prototype for a future portable and radiation-free diagnostic tool for early oncology screening and rapid triage of non-compressible haemorrhage and pneumothorax.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Sorbonne Universite | Paris | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI